BioCentury on BioBusiness,
Fourth anniversary issue; The Buyside View, V
Monday, January 6, 1997
For the middle-aged among us still able to remember the days of Catskill humor, the comedian Alan Sherman wrote a set of lyrics that could epitomize the experience of biotech investors in 1996 and their hopes for 1997:
"God rest ye merry gentlemen, let nothing you dismay,
Dis May you had a rotten month, so what is there to say,
Let's hope next May is better and good things will come your way,
And you won't have a feeling of dismay, next May."
Biotech investors are, of necessity, optimists. The sector was flat for 1996, yet by any measure, the group made fundamental progress last year, with more companies making money, more products approved, more awaiting approval, and more advancing through clinical trials. For its fifth annual review of investor sentiment for the new year, BioCentury asked institutional investors when, and how, that will be reflected in stock prices.
The problem for biotech is that it exists in a broader environment, where investors have multiple options of where to put their money. Thus 1996 was a year of contradictions for the industry
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]